story of the week
Ustekinumab Benefits Two-Thirds of Patients With Crohn's Disease Refractory to TNF Antagonists
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Clin. Gastroenterol. Hepatol. 2015 Sep 29;[EPub Ahead of Print], P Wils, Y Bouhnik, P Michetti, B Flourie, H Brixi, A Bourrier, M Allez, B Duclos, JC Grimaud, A Buisson, A Amiot, M Fumery, X Roblin, L Peyrin-Biroulet, J Filippi, G Bouguen, V Abitbol, B Coffin, M Simon, D Laharie, B ParienteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.